Uterine sarcoma: Steroid receptors and response to hormonal therapy

Wade, Kaitlin H; Quinn, Michael; Hammond, Ian; Williams, Karin; Cauchi, Maurice N.

doi:10.1016/0090-8258(90)90267-o

Cited by 66 publications

(33 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Treatment with gonadotropin-releasing hormone agonists has also been used in a few studies [14,24]. However, although the vast majority of low-grade ESS have been shown to express ER and PR, some of the tumors, even with high ER and PR content, did not respond to adjuvant hormonal treatment [6,25,30]. This could be, at least in part, due to the heterogeneity of tumor cells in terms of expression of ER and PR and the presence or absence of other steroid receptors, such as AR.…”

Section: Discussionmentioning

confidence: 98%

Expression of androgen receptors in benign and malignant endometrial stromal neoplasms

et al. 2004

View full text Add to dashboard Cite

Several studies have shown that endometrial stromal neoplasms express estrogen and progesterone receptors (ER, PR). To our knowledge, the presence or absence of androgen receptors (AR) in these rare uterine neoplasms has not been investigated. Tumors ( n=20)-3 endometrial stromal nodules, 14 low-grade endometrial stromal sarcomas (ESS, low grade), and 3 high-grade endometrial sarcomas (undifferentiated endometrial sarcoma, UES)-were studied. Immunohistochemical analyses for ER, PR, and AR were performed on formalin-fixed, paraffin-embedded archival material. Positive immunoreactions for ER and PR were observed in 14 (70%) and 17 (85%) cases, respectively. Furthermore, 9 cases (45%) were positive for AR. Among 17 ESS and UES cases, 7 (41%) revealed positivity for AR. Two of three benign stromal nodules were also positive for AR. Moreover, one of the three high-grade sarcomas (undifferentiated endometrial sarcoma) was negative for both ER and PR, but showed positive reaction for AR. In summary, ARs are expressed in 45% of endometrial stromal neoplasms. In addition to determination of ER and PR, the results of immunohistochemical examination of AR in these rare uterine tumors may have some impact on the postoperative management of the patients.

show abstract

Section: Discussionmentioning

confidence: 98%

Expression of androgen receptors in benign and malignant endometrial stromal neoplasms

et al. 2004

View full text Add to dashboard Cite

show abstract

“…A study on the presence of estrogen receptors (ER) and progesterone receptors (PR) in ESS revealed the former to be present in 7/9 and the latter in 2/9 tumors (Wade et al, 1990). The amounts of these receptors were shown to be much higher than in normal endometrium during the proliferative phase (Navarro et al, 1992).…”

Section: Steroid Receptorsmentioning

confidence: 99%

The cytogenetics and molecular biology of endometrial stromal sarcoma

Sandberg

2007

Cytogenet Genome Res

View full text Add to dashboard Cite

“…Low-grade ESS usually expresses estrogen receptors (ER) and progesterone receptors (PR), and estrogen acts as a growth stimulus [2,3]. Objective responses have been obtained with progestin therapy, such as megestrol acetate and medroxyprogesterone acetate (MPA) [4,5].…”

Section: Introductionmentioning

confidence: 99%

Aromatase inhibitor anastrozole as a second-line hormonal treatment to a recurrent low-grade endometrial stromal sarcoma: a case report

et al. 2010

View full text Add to dashboard Cite

Low-grade endometrial stromal sarcoma (ESS) is a rare neoplasm and is generally an indolent tumor with estrogen and progesterone receptors. Objective responses by hormonal treatment with progestin or aromatase inhibitor have been reported, however, long-term management of this disease could be difficult if it becomes refractory to one of these hormonal therapies. A 34-year-old woman was diagnosed with stage I low-grade ESS at the time of hysterectomy for presumed uterine fibroma. Five years later, she recurred with multiple tumors in the lower abdomen. After an optimal surgery, she was free from progression for 6 years with progestin treatment (medroxyprogesterone acetate: MPA, 200-600 mg daily). Thereafter, she recurred twice during the MPA treatment and received debulking surgery each time. MPA was discontinued at age of 53, because another recurrent tumor grew up to 13 cm in diameter. Aromatase inhibitor anastrozole was then given at a daily dose of 1 mg with partial response (the tumor size decreased to 7 cm in diameter) for a duration of 9 months. After complete resection of the recurrent tumor, she remains progression-free for 16 months. Anastrozole was effective to recurrent low-grade ESS even after being refractory to progestin therapy. Aromatase inhibitor treatment may be a useful option as a second-line hormonal treatment to low-grade ESS.

show abstract

Uterine sarcoma: Steroid receptors and response to hormonal therapy

Cited by 66 publications

References 9 publications

Expression of androgen receptors in benign and malignant endometrial stromal neoplasms

Expression of androgen receptors in benign and malignant endometrial stromal neoplasms

The cytogenetics and molecular biology of endometrial stromal sarcoma

Aromatase inhibitor anastrozole as a second-line hormonal treatment to a recurrent low-grade endometrial stromal sarcoma: a case report

Contact Info

Product

Resources

About